Initiator Pharma attends BIO 2026 in San Diego

About this update from Initiator Pharma A/s

Initiator Pharma A/S, a clinical-stage biotech company, today announced it will attend the BIO International Convention 2026, taking place on 22–25 June in San Diego, USA. Initiator Pharma’s CEO, Claus Olesen, will be available for meetings at the convention.The BIO International Convention is the world’s largest partnering event for the global biotech industry, gathering more than 20,000 delegates annually from pharmaceutical companies, investors, and research organisations. The convention is a key meeting place for partnerships, licensing deals, and life sciences investments.“BIO is a formidable arena for international business development in the biotech industry, and we enter this year’s convention in a stronger position within sexual health and neuropathic pain than ever before. The progress made in the vulvodynia study, the decision to fully commit to our lead asset pudafensine, and a strengthened IP position all contribute to a clearer and more compelling case,” says Claus Olesen, CEO of Initiator Pharma.To book a meeting with Initiator Pharma during the convention, please contact or use the BIO Partnering system.For additional information about Initiator Pharma, please contact:Claus Elsborg Olesen, CEOTelephone: +45 6126 0035E-mail: About Initiator PharmaInitiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of one clinical stage assets – pudafensine – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED.Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.Attachments

View stock analysis, news, and events for Initiator Pharma A/s